Form 8-K TOMI Environmental Solut For: Mar 30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): March 30,
2021
TOMI Environmental Solutions, Inc.
(Exact
name of registrant as specified in its charter)
Florida
|
|
000-09908
|
|
59-1947988
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
8430 Spires Way
Frederick, Maryland
21701
(Address
of principal executive offices) (Zip Code)
(800) 525-1698
(Registrant's
telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results
of Operations and Financial Condition.
On
March 30, 2021, TOMI Environmental Solutions, Inc. issued a press
release regarding its financial results for the year ended December
31, 2020. A copy of the press release is attached to this Current
Report on Form 8-K as Exhibit 99.1. No additional information is
included in this Current Report on Form 8-K.
The
information included in this Current Report on Form 8-K, including
the exhibit hereto, shall not be deemed “filed” for
purposes of, nor shall it be deemed incorporated by reference in,
any filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934, except as expressly set forth by specific
reference in such a filing.
Item
9.01 Financial
Statements and Exhibits.
(d)
Exhibits.
Exhibit Number
|
|
Description
|
|
Press
release issued March 30, 2021
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
TOMI ENVIRONMENTAL SOLUTIONS, INC.
|
|
|
|
|
Dated:
March 30, 2021
|
By:
|
/s/
Halden Shane
|
|
|
Halden
Shane
|
|
|
Chief
Executive Officer
|
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
|
Press
release issued March 30, 2021
|
Exhibit 99.1
TOMI ENVIRONMENTAL SOLUTIONS, INC. REPORTS RECORD CALENDAR YEAR 2020 REVENUE GROWTH
OF 297% TO $25 MILLION; FOURTH QUARTER SALES GROW 95% TO $3.7
MILLION
FREDERICK, MD, March 30, 2021 (BUSINESS WIRE) —
TOMI
Environmental Solutions, Inc.®
(“TOMI”)
(NASDAQ: TOMZ), is a global company specializing in disinfection and
decontamination utilizing its premier Binary Ionization Technology
(BIT) platform through its SteraMist brand of products today
announced its results financial results for the calendar year 2020
which includes annual revenue growth of 297% and a 95% increase in
fourth quarter sales.
TOMI Chief Executive Officer, Dr. Halden Shane stated, “Our
Company made tremendous progress in 2020, resulting in record
annual revenues reaching $25 million and net income of $4.4
million. The COVID-19 pandemic elevated the way the world looks at
disinfection protocols. This shift in thinking allowed us to expand
our SteraMist brand, and to onboard a diverse group of customers
from a wide range of verticals, significantly enhancing our
customer base. TOMI’s customers are great referrals for the
advancement of SteraMist technology in the marketplace and the
promotion of TOMI as a company, particularly in the emergency
services and long-term care facilities.
“Our TOMI Service Network members continue to fight at the
front lines assisting in the reopening of the economy by enabling
businesses to maintain a new level of clean. Our Life Science
division is seeing a return to normal for our current customers and
the majority of our long-term projects with top tier pharmaceutical
companies have resumed after being placed on hold due to COVID-19.
As we move through 2021, we expect the launch of new products
including the SteraBot, SteraBox, and SteraPack to drive continued
growth and meet customer demand for more agile solutions. With
these initiatives, the potential for 2021 performance is even
stronger than what we achieved in 2020. We’re excited about
the launch of these new products, which demonstrate the versatility
of our superior technology and we believe our strengthened
portfolio of offerings, coupled with our recently announced new
sales executives, position us well to continue increasing our
market share throughout 2021.”
Financial Results for the year ended December 31, 2020 compared to
December 31, 2019
●
Total net revenue was $25.0 million compared to $6.3 million, an
increase of $18.7 million or 297%.
-
SteraMist®
equipment-based
revenues were $16.9 million and $3.9 million respectively, an
increase of 333%.
-
SteraMist®
BIT
Solution-based revenues were $4.3 million and $0.7 million
respectively, an increase of 514%.
-
Service-based revenues were $2.1 million and $1.3 million,
respectively, an increase of 62%.
-
Domestic revenues were $18.4 million and $5.0 million,
respectively, an increase of 268%; International revenues were
approximately $6.7 million and $1.3 million, respectively, an
increase of 415%.
●
Gross margin was 60.1% compared to 61.7%. The decrease in gross
profit is attributable to product mix.
●
Operating income was $4.5 million compared to an operating loss of
($2.1 million).
●
Net Income was $4.4 million or $0.27 per basic and $0.23 per
diluted share, compared to a net loss of $2.3 million or ($0.15)
per basic and diluted share.
●
EBITDA was $5.2 million compared to an EBITDA loss of ($1.4
million). A table reconciling EBITDA to the appropriate GAAP
measure is included with the Company's financial information
below.
●
Adjusted EBITDA was $8.4 million as compared to adjusted EBITDA
loss of ($1.2 million). Adjusted EBITDA margin was 33% for full
year 2020. A table reconciling Adjusted EBITDA to the appropriate
GAAP measure is included with the Company's financial information
below.
●
Cash provided from operations for the year ended December 31, 2020
was $4.6 million compared to cash used in operations of ($814,000)
for the year ended December 31, 2019.
Financial Results for the three months ended December 31, 2020
compared to December 31, 2019
●
Total net revenue was $3.7 million compared to $1.9 million, an
increase of 95%.
-
SteraMist®
equipment-based
revenues were $2.3 million and $1.3 million respectively, an 77%
increase.
-
SteraMist®
BIT
Solution-based revenues were $0.8 million and $0.2 million,
respectively, an increase of 300%.
-
Service-based revenues were $0.2 million and $0.3 million,
respectively, a decrease of 33%.
-
Domestic revenues were $2.9 million and $1.2 million ,
respectively, an increase of 142%; International revenues were
consistent at approximately $0.7 million in both 2020 and
2019.
●
Gross margin was 58.9% compared to 56.0%. The increased gross
margin is attributable to product mix.
●
Operating loss was ($2.9 million) compared to an operating loss of
($0.5 million). The increased loss from operations is attributable
to non-cash equity compensation expense charge incurred in the
fourth quarter in the amount of $2.8 million.
●
Net loss was ($2.9 million) or ($0.17) per basic and diluted share,
compared to a net loss of ($0.5 million) or ($0.03) per basic and
diluted share.
●
EBITDA loss was ($2.7 million) and ($0.3 million). A table
reconciling EBITDA to the appropriate GAAP measure is included with
the Company's financial information below.
●
Adjusted EBITDA was $0.1 million compared to EBITDA loss of ($0.3
million). A table reconciling Adjusted EBITDA to the appropriate
GAAP measure is included with the Company's financial information
below.
Balance sheet highlights as of December 31, 2020
●
Cash and cash equivalents were approximately $5.2 million compared
to $0.9 million at December 31, 2019, an increase of $4.3 million
.
●
Working capital was $11.5 million compared to ($1.3 million) at
December 31, 2019.
●
Shareholders’ equity was $13.2 million compared to $0.9
million at December 31, 2019, an increase of $12.3
million.
Current Business Highlights To Date
Revenues
●
Record total revenue exceeding $25 million in a calendar
year.
●
Added approximately 250 new customers across our five divisions for
the year ended December 31, 2020.
●
Sold 650 machines and
29,000 gallons of our SteraMist®
BIT
Solution during 2020 calendar year.
Business Highlights
●
Conversion of $4.5 million convertible note into shareholder
equity.
●
Effected a 1-for-8 reverse stock split of the outstanding shares of
our common stock and preferred A stock; Common stock was approved
for listing on the Nasdaq Stock Market and our shares commenced
trading on the Nasdaq Stock Market on October 1, 2020.
●
Added additional manufacturer through agreement with Planet
Innovation.
●
TOMI Service Network provider memberships increased and BIT
solution sales dramatically increased related to the number of
service jobs conducted by TSN providers, including the treatment of
schools, residential and commercial buildings, rapid transit,
airplanes and other transportation methods.
●
Launched our Commercial Division to capitalize on increased demand
from Federal Government facilities and agencies, the aircraft
industry, manufacturing companies, the automobile, naval,
education, retail, housing and recreation sectors, and emergency
preparedness for counties and cities.
●
SteraMist equipment and BIT solution officially approved and
registered with the China CDC (Received two separate
registrations).
●
Successfully tested for direct produce application efficacy, with
testing results published in Food Control for the third time,
highlighting the USDA paper “Cold plasma-activated hydrogen
peroxide aerosol on populations of Salmonella Typhimurium and
Listeria innocua and quality changes of apple, tomato and
cantaloupe during storage – A pilot scale study”
authored by Dr. Xuetong Fan. The study sought to test direct
application of iHP™ directly onto the smooth surfaces of
tomatoes and apples, the stem scars of of tomatoes, and the rinds
of cantaloupes. Resulting efficacy on the reduction of Salmonella
Typhimurium and Listeria innocua bacteria as well as any changes in
quality parameters for simulated storage were
observed.
●
Released preliminary scientific results on one of two studies
conducted with the University of Virginia demonstrating kill on
SARS CoV-2 Virus in five seconds. The Company looks forward to
results on the second study achieving kill on Adenovirus, which
will benefit the TOMI’s efforts in the Hospital-HealthCare,
TOMI Service Network, and Commercial markets.
●
Continued development and testing of the “SteraBot” and
launch of pilot program at Lithuanian University
Hospital.
●
Ongoing development of new products such as SteraBox and SteraPack,
with the latter to have a tentative launch set for second quarter
2021.
●
Received first Australian patent protecting use of its iHP
technology, and pursuing patent rights in diverse regions of the
world, encompassing the European Union, Brazil, Mexico, Korea,
China, India, and many other countries.
●
Added three Vice Presidents of Sales to
oversee the Company’s sales efforts, to capitalize on the
growing pipeline of opportunites across
the Commercial, Healthcare and Food Divisions
respectively.
●
Increased demand for TOMI’s product and services has led to
the hiring and onboarding of additional employees to assist in a
wide variety of company operations, including accounting,
procurement, customer satisfaction, and quality
control.
TOMI™ Environmental Solutions, Inc.: Innovating for a
safer world®
TOMI™ Environmental Solutions, Inc.
(NASDAQ:TOMZ)
is a global decontamination and infection prevention company,
providing environmental solutions for indoor surface disinfection
through the manufacturing, sales and licensing of its premier
Binary Ionization Technology® (BIT™) platform.
Invented under a defense grant in association with the Defense
Advanced Research Projects Agency (DARPA) of the U.S. Department of
Defense, BIT™ solution utilizes a low percentage
Hydrogen Peroxide as its only active ingredient to produce a fog of
ionized Hydrogen Peroxide (iHP™). Represented by the
SteraMist® brand of products, iHP™ produces a
germ-killing aerosol that works like a visual non-caustic
gas.
TOMI products are designed to service a broad spectrum of
commercial structures, including, but not limited to, hospitals and
medical facilities, cruise ships, office buildings, hotel and motel
rooms, schools, restaurants, meat and produce processing
facilities, military barracks, police and fire departments, and
athletic facilities. TOMI products and services have also
been used in single-family homes and multi-unit
residences.
TOMI develops training programs and application protocols for
its clients and is a member in good standing with The American
Biological Safety Association, The American Association of Tissue
Banks, Association for Professionals in Infection Control and
Epidemiology, Society for Healthcare Epidemiology of America,
America Seed Trade Association, and The Restoration Industry
Association.
For additional information, please visit http://www.tomimist.com/ or
contact us at [email protected].
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995
Certain written and oral statements made by us may constitute
“forward-looking statements” as defined in the Private
Securities Litigation Reform Act of 1995 (the “Reform
Act”). Forward-looking statements are identified by such
words and phrases as “we expect,” “expected
to,” “estimates,” “estimated,”
“current outlook,” “we look forward to,”
“would equate to,” “projects,”
“projections,” “projected to be,”
“anticipates,” “anticipated,” “we
believe,” “could be,” and other similar phrases.
All statements addressing operating performance, events, or
developments that we expect or anticipate will occur in the future,
including statements relating to revenue growth, earnings,
earnings-per-share growth, or similar projections, are
forward-looking statements within the meaning of the Reform Act.
They are forward-looking, and they should be evaluated in light of
important risk factors that could cause our actual results to
differ materially from our anticipated results. The information
provided in this document is based upon the facts and circumstances
known at this time. We undertake no obligation to update these
forward-looking statements after the date of this
release.
Use of Non-GAAP Financial Measures
This press release includes information relating to EBITDA,
Adjusted EBITDA and Adjusted EBITDA margin, each of which the
Securities and Exchange Commission has defined as a "non-GAAP
financial measure."
We define EBITDA as net income (loss), adjusted to exclude:
interest, taxes, depreciation and amortization (EBITDA) is a
non-GAAP financial measure and is intended to serve as a supplement
to our results provided in accordance with GAAP. We believe that
such information may provide our investors a better understanding
of our underlying operational performance, business and performance
trends.
We define Adjusted EBITDA as net income (loss), adjusted to
exclude: interest, taxes, depreciation and amortization;
stock-based compensation expense. We define Adjusted EBITDA margin
as Adjusted EBITDA divided by net revenue. We believe that such
information may provide our investors a better understanding of our
underlying operational performance, business and performance
trends.
Although we believe that the use of non-GAAP financial measures
enhance its investors’ understanding of its business and
performance, our use of non-GAAP financial measures should not be
considered an alternative to GAAP basis financial measures and
should be read in conjunction with the relevant GAAP financial
measures. Other companies in similar industries may define or
calculate non-GAAP financial measures differently than ours,
limiting their usefulness as a comparative measure. Because of
these limitations, the non-GAAP financial measure used in this
release should not be considered in isolation or as a substitute
for performance measures calculated in accordance with GAAP. A
reconciliation of the non-GAAP financial measures to the most
directly comparable GAAP measure is available in this news
release.
TOMI
ENVIRONMENTAL SOLUTIONS, INC.
|
||
CONSOLIDATED
BALANCE SHEET
|
||
|
|
|
ASSETS
|
|
|
Current
Assets:
|
|
|
Current
Assets:
|
December 31, 2020
(1)
|
December 31, 2019
(1)
|
Cash and Cash
Equivalents
|
$5,198,842
|
$897,223
|
Accounts Receivable
- net
|
3,716,701
|
1,494,658
|
Other
Receivables
|
198,951
|
-
|
Inventories
|
3,781,515
|
2,315,214
|
Vendor
Deposits
|
388,712
|
141,052
|
Prepaid
Expenses
|
421,305
|
187,664
|
Total
Current Assets
|
13,706,027
|
5,035,811
|
|
|
|
Property and
Equipment – net
|
1,298,103
|
1,367,864
|
|
|
|
Other
Assets:
|
|
|
Intangible Assets
– net
|
722,916
|
939,010
|
Operating Lease -
Right of Use Asset
|
631,527
|
674,471
|
Capitalized
Software Development Costs - net
|
52,377
|
94,278
|
Other
Assets
|
358,935
|
114,033
|
Total
Other Assets
|
1,765,755
|
1,821,792
|
Total
Assets
|
$16,769,885
|
$8,225,467
|
Current
Liabilities:
|
|
|
LIABILITIES
AND SHAREHOLDERS’ EQUITY
|
|
|
Accounts
Payable
|
$1,501,469
|
$713,222
|
Accrued
Expenses and Other Current Liabilities
|
501,849
|
450,112
|
Accrued
Interest
|
-
|
66,667
|
Customer
Deposits
|
118,880
|
-
|
Current
Portion of Long-Term Operating Lease
|
81,223
|
71,510
|
Convertible
Notes Payable, net of discount of $0
|
|
|
at
December 31, 2019
|
-
|
5,000,000
|
Total
Current Liabilities
|
2,203,421
|
6,301,511
|
|
|
|
Long-Term
Liabilities:
|
|
|
Loan
Payable (Note 16)
|
410,700
|
-
|
Long-Term
Operating Lease, Net of Current Portion
|
953,190
|
1,034,413
|
Total
Long-Term Liabilities
|
1,363,890
|
1,034,413
|
Total
Liabilities
|
3,567,311
|
7,335,924
|
|
|
|
Commitments
and Contingencies
|
-
|
-
|
|
|
|
Shareholders’
Equity:
|
|
|
Cumulative
Convertible Series A Preferred Stock;
|
|
|
par
value $0.01 per share, 1,000,000 shares authorized; 63,750 shares
issued
|
|
|
and
outstanding at December 31, 2020 and December 31, 2019
|
638
|
638
|
Cumulative
Convertible Series B Preferred Stock; $1,000 stated
value;
|
|
|
7.5%
Cumulative dividend; 4,000 shares authorized; none
issued
|
|
|
and
outstanding at December 31, 2020 and December 31, 2019
|
-
|
-
|
Common
stock; par value $0.01 per share, 250,000,000 shares
authorized;
|
|
|
16,761,513
and 15,587,552 shares issued and outstanding
|
|
|
at
December 31, 2020 and December 31, 2019, respectively.
|
167,615
|
155,875
|
Additional
Paid-In Capital
|
52,142,399
|
44,232,274
|
Accumulated
Deficit
|
(39,108,078)
|
(43,499,244)
|
Total
Shareholders’ Equity
|
13,202,574
|
889,543
|
Total Liabilities
and Shareholders’ Equity
|
$16,769,885
|
$8,225,467
|
(1) Share amounts with respect to the common stock and Convertible
Series A Preferred Stock have been retroactively restated to
reflect the reverse split thereof, which was effected as of the
close of business on September 10,
2020.
CONSOLIDATED
STATEMENT OF OPERATIONS
|
||||
|
|
|
|
|
|
For The Three
Months Ended
|
For The Years
Ended
|
||
|
December
31,
|
December
31,
|
||
|
2020
|
2019
|
2020
|
2019
|
|
|
|
|
|
Sales,
net
|
$3,654,133
|
$1,855,441
|
$25,027,637
|
$6,347,160
|
Cost
of Sales
|
1,500,466
|
816,563
|
9,985,046
|
2,433,243
|
Gross
Profit
|
2,153,667
|
1,038,878
|
15,042,591
|
3,913,917
|
|
|
|
|
|
Operating
Expenses:
|
|
|
|
|
Professional
Fees
|
262,861
|
66,440
|
681,377
|
363,789
|
Depreciation
and Amortization
|
198,274
|
177,095
|
719,760
|
716,165
|
Selling
Expenses
|
267,348
|
380,238
|
1,247,444
|
1,654,564
|
Research
and Development
|
209,603
|
91,209
|
455,046
|
340,582
|
Equity
Compensation Expense
|
2,823,300
|
27,189
|
3,130,986
|
114,222
|
Consulting
Fees
|
100,778
|
39,627
|
327,232
|
126,693
|
General
and Administrative
|
1,195,110
|
749,376
|
3,971,956
|
2,681,146
|
Total Operating
Expenses
|
5,057,275
|
1,531,174
|
10,533,802
|
5,997,161
|
Income (loss) from
Operations
|
(2,903,608)
|
(492,296)
|
4,508,789
|
(2,083,244)
|
|
|
|
|
|
Other Income
(Expense):
|
|
|
|
|
Amortization
of Debt Discounts
|
-
|
-
|
-
|
(17,534)
|
Interest
Income
|
568
|
613
|
2,915
|
3,045
|
Interest
Expense
|
(1,272)
|
(50,000)
|
(43,538)
|
(200,000)
|
Total Other Income
(Expense)
|
(704)
|
(49,387)
|
(40,623)
|
(214,489)
|
|
|
|
|
|
Income (loss)
before income taxes
|
(2,904,312)
|
(541,683)
|
4,468,166
|
(2,297,733)
|
Provision for
Income Taxes
|
-
|
-
|
77,000
|
-
|
Net Income
(loss)
|
$(2,904,312)
|
$(541,683)
|
$4,391,166
|
$(2,297,733)
|
|
|
|
|
|
Net income (loss)
Per Common Share
|
|
|
|
|
Basic
|
$(0.17)
|
$(0.03)
|
$0.27
|
$(0.15)
|
Diluted
|
$(0.17)
|
$(0.03)
|
$0.23
|
$(0.15)
|
|
|
|
|
|
Basic Weighted
Average Common Shares Outstanding
|
16,759,058
|
15,587,552
|
16,512,126
|
15,586,258
|
Diluted Weighted
Average Common Shares Outstanding
|
16,759,058
|
15,587,552
|
18,757,509
|
15,586,258
|
(1)
Share amounts with respect to the common stock and Convertible
Series A Preferred Stock have been retroactively restated to
reflect the reverse split thereof,
which was effected as of the close of business on September 10,
2020.
The following is a reconciliation of net income (loss) to EBITDA
and Adjusted EBITDA (in thousands, except percentages;
unaudited):
|
For The Three
Months Ended
|
For The Year
Ended
|
||
|
December
31,
|
December
31,
|
||
|
2020
|
2019
|
2020
|
2019
|
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
Net income
(loss)
|
$(2,904,312)
|
$(541,683)
|
$4,391,166
|
$(2,297,733)
|
|
|
|
|
|
Interest
Income
|
(568)
|
(613)
|
(2,915)
|
(3,045)
|
Interest
Expense
|
1,272
|
50,000
|
43,538
|
200,000
|
Depreciation
and Amortization
|
198,274
|
177,095
|
719,760
|
716,165
|
Provision
for Income Taxes
|
-
|
|
77,000
|
|
Other
|
-
|
-
|
-
|
17,534
|
EBITDA
|
$(2,705,334)
|
$(315,201)
|
$5,228,549
|
$(1,367,079)
|
|
|
|
|
|
Equity Compensation
Expense
|
2,823,300
|
10,621
|
3,130,986
|
114,222
|
Adjusted
EBITDA
|
$117,996
|
$(304,580)
|
$8,359,535
|
$(1,252,857)
|
|
|
|
|
|
Net
revenue
|
$3,654,133
|
$1,855,441
|
$25,027,637
|
$6,347,160
|
Adjusted EBITDA
Margin
|
3%
|
(16%)
|
33%
|
(20%)
|
INVESTOR RELATIONS CONTACT:
John Nesbett/Jennifer Belodeau
IMS Investor Relations
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corporate Wellness Market to Boom at a CAGR of 7.8%, Reaching USD 120.15 Billion by 2031
- Landsbankinn hf.: Financial results for Q1 2024 to be published 2 May 2024
- Tool Steel Market to Reach USD 10.54 Billion by 2031 Driven by Booming Manufacturing and Construction Sectors
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!